DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now available in retail pharmacies
Medunik USA, a company dedicated to improving the health and quality of life of Americans with rare diseases by making orphan drugs available in the U.S., announced today that Siklos® (hydroxyurea), an FDA-approved orphan drug, is now available in 100 mg tablets for pharmacies to order.
Siklos® is indicated to reduce the frequency of painful crises and the need for blood transfusions in pediatric patients, two years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises. It is the first and only FDA-approved hydroxyurea-based treatment for use in pediatric patients with sickle cell anemia.
Medunik USA holds the exclusive rights to market and distribute Siklos® in the United States, through an agreement with ADDMEDICA, a French pharmaceutical company specializing in hematology.
news & eventsSickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study FindsIntensifying treatment with hydroxyurea ...
videos & visualsIs Your Child the Right Candidate for Hydroxyureahttps://www.youtube.com/watch?v=vMvC5rVH...
people & placesAisha Walker, PhDDr. Walker is a Research Assistant Profe...
education & researchEffects of Hydroxyurea (HU) on Neurocognitive Performance in Children With Sickle Cell Disease: A Prospective TrialSickle cell anemia is associated with pr...
education & researchHydroxyurea for Sickle Cell DiseaseHydroxyurea is a medicine that doctors h...
news & eventsFDA Approves Hydroxyurea Tablets for Pediatric Patients With Sickle Cell AnemiaThe US Food and Drug Administration (FDA...
news & eventsDiscovery could help treatments for sickle cell diseaseResearch team establishes biomarkers for...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.